Avacta Group (AVCT) Corporate presentation summary

Platform innovation and mechanism of action

• Next generation peptide drug conjugates (PDCs) use tumor-activated, FAP-specific cleavage for controlled payload release, minimizing toxicity and maximizing tumor concentration.

• The pre|CISION® platform enables robust efficacy, rapid tumor penetration, and high selectivity by releasing potent drugs only in the tumor microenvironment.

• Controlled release chemistry allows for slow, sustained payload delivery, reducing systemic exposure and improving safety.

• Dual payload technology is being developed to address therapy resistance by releasing two drugs from a single cleavage event.

• The platform is applicable to ~90% of solid tumors due to widespread FAP expression.

Clinical pipeline and trial progress

• Lead asset AVA6103 (FAP-Exd) is in Phase 1 trials across six solid tumor indications, with initial proof-of-mechanism data expected in Q3 2026.

• AVA6103 demonstrates superior tumor selectivity, higher intratumoral drug levels, and a favorable safety profile compared to Enhertu and exatecan.

• AVA6207, a dual payload candidate, is advancing toward IND-enabling studies with high tumor selectivity for both payloads.

• First-generation AVA6000 showed proof of concept, with optimized safety and durable responses in FAP-negative tumors.

• Multiple data catalysts are anticipated through 2027, including efficacy readouts and candidate selections.

Preclinical and clinical data highlights

• AVA6103 achieves rapid and sustained tumor drug release, with plasma levels dropping quickly and tumor levels maintained for at least five days.

• In preclinical models, AVA6103 outperformed Enhertu in HER2+ gastric cancer, enabling dose intensification without increased toxicity.

• Clinical PK data align closely with preclinical models, confirming the controlled release mechanism in patients.

• AVA6103 releases approximately three times less exatecan in plasma than equivalent doses of Enhertu, supporting improved safety.

• Dual payload AVA6207 achieves high tumor selectivity indices for both topoisomerase I and ATR inhibitors.